JP2023531729A5 - - Google Patents
Info
- Publication number
- JP2023531729A5 JP2023531729A5 JP2022579985A JP2022579985A JP2023531729A5 JP 2023531729 A5 JP2023531729 A5 JP 2023531729A5 JP 2022579985 A JP2022579985 A JP 2022579985A JP 2022579985 A JP2022579985 A JP 2022579985A JP 2023531729 A5 JP2023531729 A5 JP 2023531729A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- lymphocytes
- exon
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063044697P | 2020-06-26 | 2020-06-26 | |
| US63/044,697 | 2020-06-26 | ||
| PCT/US2021/039022 WO2021263070A1 (en) | 2020-06-26 | 2021-06-25 | Donor t-cells with kill switch |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023531729A JP2023531729A (ja) | 2023-07-25 |
| JP2023531729A5 true JP2023531729A5 (enExample) | 2024-12-13 |
Family
ID=77022239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022579985A Pending JP2023531729A (ja) | 2020-06-26 | 2021-06-25 | キルスイッチを有するドナーｔ細胞 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230355674A1 (enExample) |
| EP (1) | EP4172335A1 (enExample) |
| JP (1) | JP2023531729A (enExample) |
| CN (1) | CN115997015A (enExample) |
| AU (1) | AU2021294317A1 (enExample) |
| WO (1) | WO2021263070A1 (enExample) |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5958928A (en) | 1995-03-27 | 1999-09-28 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical agents containing methotrexate derivative |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| EP1191097A1 (en) | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
| EP2933332A1 (en) | 2004-06-28 | 2015-10-21 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| WO2007098089A2 (en) | 2006-02-17 | 2007-08-30 | Novacea, Inc. | Treatment of hyperproliferative diseases with methotrexate n-oxide and analogs |
| CN103849629B (zh) | 2006-06-21 | 2017-06-09 | 尤尼克尔Ip股份有限公司 | 具有经修饰的用于在昆虫细胞中产生aav的aav‑rep78翻译起始密码子的载体 |
| BR122020021379B1 (pt) | 2008-10-24 | 2021-05-11 | Sarepta Therapeutics, Inc. | oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular |
| TR201816523T4 (tr) | 2009-11-12 | 2018-11-21 | Univ Western Australia | Patolojilerin tedavisine yönelik antisens moleküller ve yöntemler. |
| US9283194B2 (en) | 2010-04-16 | 2016-03-15 | The Regents Of The University Of California | Methods for protease assisted protein delivery |
| US9993440B2 (en) | 2011-09-02 | 2018-06-12 | The Regents Of The University Of California | Enzyme responsive nanocapsules for protein delivery |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| CA2907095C (en) | 2012-03-16 | 2020-11-03 | The Regents Of The University Of California | A novel rnai molecule delivery platform based on single-sirna and shrna nanocapsules |
| HUE054260T2 (hu) | 2012-09-06 | 2021-08-30 | Univ Chicago | Antiszensz polinukleotidok exon-ugrás indukálására és eljárások disztrófiák kezelésére |
| JP6502261B2 (ja) | 2012-12-14 | 2019-04-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ターゲティング遺伝子治療のためのウイルスベクターナノカプセル、およびその調製 |
| US20140329762A1 (en) | 2013-03-15 | 2014-11-06 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
| CN105683376A (zh) * | 2013-05-15 | 2016-06-15 | 桑格摩生物科学股份有限公司 | 用于治疗遗传病状的方法和组合物 |
| CN107530445B (zh) | 2014-11-26 | 2021-01-05 | 加利福尼亚大学董事会 | 用于蛋白质递送的隐形纳米胶囊 |
| HK1247963A1 (zh) | 2015-05-18 | 2018-10-05 | Csl贝林基因治疗股份有限公司 | 用於hiv的治疗的基因疗法及其用途 |
| GB2592821B (en) * | 2015-07-31 | 2022-01-12 | Univ Minnesota | Modified cells and methods of therapy |
| EP3463428A4 (en) | 2016-05-24 | 2020-01-08 | The Regents of the University of California | GROWTH FACTOR NANO CAPSULES WITH TUNABLE RELEASE FOR BONE REGENERATION |
| WO2018164457A1 (ko) * | 2017-03-06 | 2018-09-13 | 기초과학연구원 | C2cL 엔도뉴클레아제를 포함하는 유전체 교정용 조성물 및 이를 이용한 유전체 교정 방법 |
| JP7410856B2 (ja) * | 2017-07-18 | 2024-01-10 | シーエスエル・ベーリング・ジーン・セラピー・インコーポレイテッド | ドナー改変細胞の選択のための調節可能スイッチ |
| US20210228630A1 (en) * | 2018-05-16 | 2021-07-29 | Research Institute At Nationwide Children's Hospital | Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins |
| KR20210118833A (ko) * | 2018-12-23 | 2021-10-01 | 씨에스엘 베링 엘엘씨 | 킬 스위치를 갖는 공여 t 세포 |
-
2021
- 2021-06-25 WO PCT/US2021/039022 patent/WO2021263070A1/en not_active Ceased
- 2021-06-25 CN CN202180045426.7A patent/CN115997015A/zh active Pending
- 2021-06-25 EP EP21745541.9A patent/EP4172335A1/en active Pending
- 2021-06-25 AU AU2021294317A patent/AU2021294317A1/en active Pending
- 2021-06-25 JP JP2022579985A patent/JP2023531729A/ja active Pending
-
2022
- 2022-12-11 US US18/078,977 patent/US20230355674A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230287401A1 (en) | Rna guided compositions for preventing and treating hepatitis b virus infections | |
| JP7176737B2 (ja) | レトロウイルス核酸配列の切除 | |
| JP5711666B2 (ja) | 白血球への効率的輸送 | |
| JP2019517503A (ja) | 遺伝子編集戦略によるｈｉｖ−１のネガティブフィードバック調節 | |
| JP2018531261A6 (ja) | Ｃｐｆ１を用いた、ｒｎａガイド遺伝子編集方法および組成物 | |
| JP2018531261A (ja) | Ｃｐｆ１を用いた、ｒｎａガイド遺伝子編集方法および組成物 | |
| JP2018527943A (ja) | Ｒｎａ誘導性の、ｈｉｖ感染の処置のための、方法および組成物 | |
| CN107075515A (zh) | C/EBPα组合物和使用方法 | |
| JP2020530463A (ja) | ウイルスの細胞内送達のためのペプチドおよびナノ粒子 | |
| JP7385847B2 (ja) | ｓｎｏＲＮＡの発現抑制剤を有効成分とするがん増殖抑制剤 | |
| JP2021515576A5 (enExample) | ||
| JP2004528266A (ja) | 薬物送達用組成物 | |
| WO2019183246A1 (en) | Compositions and methods of fas inhibition | |
| JP2022543446A (ja) | Ａｐｏｅ４ ｒｎａ特異的トランススプライシングリボザイム及びその用途 | |
| WO2018194876A1 (en) | An hiv-1 eradication strategy employing nanoformulated anti-retroviral drugs and gene editing agents | |
| JP2022514954A5 (enExample) | ||
| JP2023531729A5 (enExample) | ||
| US20240123034A1 (en) | Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease | |
| US20190085326A1 (en) | Negative feedback regulation of HIV-1 by gene editing strategy | |
| EP3884055A1 (en) | Double and inducible suicide gene construct and its use in gene therapy | |
| CN115161289B (zh) | 一种用于炎症性疾病治疗的重组腺相关病毒及其构建方法和应用 | |
| US20240318147A1 (en) | Recombinant oncolytic virus, and construction method therefor and use thereof | |
| US20230070049A1 (en) | Microrna-7 compositions for promoting functional recovery following spinal cord injury and methods of use thereof | |
| Akki et al. | A Review Article on Gene Therapy | |
| Nabel | Gene therapy approaches to AIDS |